H
Haley E. Manchester
Researcher at Harvard University
Publications - 5
Citations - 759
Haley E. Manchester is an academic researcher from Harvard University. The author has contributed to research in topics: Chromatin remodeling & Synthetic lethality. The author has an hindex of 4, co-authored 5 publications receiving 537 citations. Previous affiliations of Haley E. Manchester include Brigham and Women's Hospital & Boston Children's Hospital.
Papers
More filters
Journal ArticleDOI
ARID1B is a specific vulnerability in ARID1A-mutant cancers
Katherine C. Helming,Xiaofeng Wang,Boris G. Wilson,Francisca Vazquez,Jeffrey R. Haswell,Haley E. Manchester,Youngha Kim,Gregory V. Kryukov,Mahmoud Ghandi,Andrew J. Aguirre,Zainab Jagani,Zhong Wang,Levi A. Garraway,William C. Hahn,Charles W. M. Roberts +14 more
TL;DR: It is found that loss of ARID1B in AR ID1A-deficient backgrounds destabilizes SWI/SNF and impairs proliferation in both cancer cells and primary cells, and is identified as a potential therapeutic target for ARID 1A-mutant cancers.
Journal ArticleDOI
The SWI/SNF chromatin remodelling complex is required for maintenance of lineage specific enhancers.
Burak H. Alver,Kimberly H. Kim,Ping Lu,Ping Lu,Xiaofeng Wang,Xiaofeng Wang,Haley E. Manchester,Haley E. Manchester,Weishan Wang,Weishan Wang,Jeffrey R. Haswell,Jeffrey R. Haswell,Peter J. Park,Charles W. M. Roberts +13 more
TL;DR: It is shown via ChIP-seq and biochemical assays that SWI/SNF complexes are preferentially targeted to distal lineage specific enhancers and interact with p300 to modulate histone H3 lysine 27 acetylation, establishingSWI/ SNF complexes as regulators of the enhancer landscape and providing insight into the roles of SWI-SNF in cellular fate control.
Journal ArticleDOI
Melanoma Therapeutic Strategies that Select against Resistance by Exploiting MYC-Driven Evolutionary Convergence
Katherine R. Singleton,Lorin Crawford,Elizabeth Tsui,Haley E. Manchester,Ophélia Maertens,Ophélia Maertens,Xiaojing Liu,Maria V. Liberti,Anniefer N. Magpusao,Elizabeth M. Stein,Jennifer P. Tingley,Dennie T. Frederick,Genevieve M. Boland,Keith T. Flaherty,Shannon J. McCall,Clemens Krepler,Katrin Sproesser,Meenhard Herlyn,Drew J. Adams,Jason W. Locasale,Karen Cichowski,Sayan Mukherjee,Kris C. Wood +22 more
TL;DR: It is discovered that major pathways of resistance converge to activate the transcription factor, c-MYC (MYC), and MYC-driven, BRAFi-resistant cells are hypersensitive to the inhibition of MYC synthetic lethal partners, including SRC family and c-KIT tyrosine kinases, as well as glucose, glutamine, and serine metabolic pathways.
Journal ArticleDOI
MAPK pathway suppression unmasks latent DNA repair defects and confers a chemical synthetic vulnerability in BRAF, NRAS, and NF1 mutant melanomas
Ophélia Maertens,Ophélia Maertens,Ryan Kuzmickas,Ryan Kuzmickas,Haley E. Manchester,Haley E. Manchester,Chloe E. Emerson,Chloe E. Emerson,Alessandra G. Gavin,Alessandra G. Gavin,Caroline J. Guild,Caroline J. Guild,Terence C. Wong,Terence C. Wong,Thomas De Raedt,Thomas De Raedt,Christian Bowman-Colin,Elodie Hatchi,Levi A. Garraway,Keith T. Flaherty,Shailja Pathania,Stephen J. Elledge,Karen Cichowski,Karen Cichowski +23 more
TL;DR: Together, these studies identify melanomas with latent DNA repair defects, describe a promising drug combination that capitalizes on these defects, and reveal a clinical biomarker that predicts responsiveness, a tractable therapeutic biomarker.
Proceedings ArticleDOI
Abstract LB-126: ARID1B is a specific vulnerability in ARID1A-mutant cancers
Katherine C. Helming,Xiaofeng Wang,Boris G. Wilson,Francisca Vazquez,Jeffrey R. Haswell,Haley E. Manchester,Youngha Kim,Gregory V. Kryukov,Mahmoud Ghandi,Andrew J. Aguirre,Zainab Jagani,Zhong Wang,Levi A. Garraway,William C. Hahn,Charles W. M. Roberts +14 more
TL;DR: It is demonstrated that cancer cell lines harboring mutations in ARID1A are specifically dependent upon ARIDs1B and insight is provided into the structural role of ARid1A/B in the SWI/SNF chromatin remodeling complex.